What is currently being studied for visceral fat?
The evidence depends on the population and the question. An approved indication, obesity treatment, and investigational research should not be collapsed into one list.
DIRECT ANSWER
Evidence-based answer.
The evidence depends on the population and the question. An approved indication, obesity treatment, and investigational research should not be collapsed into one list.
Reviewed August 7, 2026. Each statement links to its evidence record, followed by the primary and official sources used for this answer.
Tesamorelin has randomized human evidence and an FDA-approved indication for reducing excess abdominal fat in adults with HIV and lipodystrophy—not general weight-loss management.
Open evidence recordSemaglutide and tirzepatide have large human evidence programs for labeled metabolic indications, but their evidence is not specific to the same HIV-lipodystrophy question.
Open evidence recordRetatrutide has published randomized Phase 2 evidence and late-stage research, but it remains investigational and is not FDA approved.
Open evidence recordMOTS-c has interesting metabolic biology, but current human studies do not establish injected MOTS-c as a visceral-fat therapy.
Open evidence recordPRIMARY & OFFICIAL SOURCES
Sources for this answer.
9 source records, with duplicates removed.